URGN vs VIR: Which Stock Is the Better Buy?
UroGen Pharma Ltd. and Vir Biotechnology, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — URGN vs VIR, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| UroGen Pharma Ltd. (URGN) | Vir Biotechnology, Inc. (VIR) | |
|---|---|---|
| Market cap | $1.4B | $1.4B |
| Revenue (latest FY) | $109.79M | $68.56M |
| Net income (latest FY) | $-153.49M | $-437.99M |
| Revenue growth (5y CAGR) | 56.2% | -2.1% |
| Net margin | -139.8% | -638.9% |
| Return on equity | 145.5% | -57.2% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 2 |
| Positive free cash flow | No | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full URGN vs VIR breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open URGN's full financials → Open VIR's full financials →More comparisons
Frequently asked questions
Which is bigger, URGN or VIR?
Vir Biotechnology, Inc. is larger by market capitalization — $1.4B versus $1.4B.
Which grows faster, URGN or VIR?
Over the last five fiscal years, UroGen Pharma Ltd. grew revenue faster — 56.2%/yr versus -2.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.